Based on data from PASNA patients (11) and the discovery of somatic Cav1.3 gain-of-function mutations in aldosterone producing adenomas (15), the patient should instead be closely monitored for hyperaldosteronism. This evidence concerns the gene CACNA1D and hyperaldosteronism.